Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

Published:2012-11-15 Issue:3 Volume:160 Page:321-330
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Berenson James R.,Yellin Ori¹,Bessudo Alberto²,Boccia Ralph V.³,Noga Stephen J.⁴,Gravenor Donald S.⁵,Patel-Donnelly Dipti⁶,Siegel Robert S.⁷,Kewalramani Tarun⁸,Gorak Edward J.⁹,Nassir Youram¹⁰,Swift Regina A.¹¹,Mayo Debra¹²

Affiliation:

1. Oncotherapeutics; West Hollywood; CA; USA

2. San Diego Pacific Oncology Hematology Associates, Inc.; Encinitas; CA; USA

3. Center for Cancer and Blood Disorders; Bethesda; MD; USA

4. Weinberg Cancer Institute at Franklin Square Hospital; Baltimore; MD; USA

5. Family Cancer Center Foundation; Memphis; TN; USA

6. Virginia Cancer Specialists, PC; Fairfax; VA; USA

7. George Washington University - Medical Faculty Associates; Washington; DC; USA

8. Lahey Clinic; Burlington; MA; USA

9. Geisinger Medical Center; Danville; PA; USA

10. Cancer Care Institute; Los Angeles; CA; USA

11. James R. Berenson, MD, Inc.; Los Angeles; CA; USA

12. Teva Pharmaceutical Industries Ltd.; Frazer; PA; USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12129/fullpdf

Reference49 articles.

1. Multiple myeloma: how far have we come?;Anderson;Mayo Clinic Proceedings,2003

2. Updated survival analysis of a randomized, phase 3 study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma;Arnulf;Haematologica,2012

3. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome;Attal;The New England Journal of Medicine,1996

4. A phase II trial of combined bendamustine, bortezomib and dexamethasone in newly diagnosed multiple myeloma (MM) patients who are not candidates for high-dose chemotherapy: results of a planned interim safety analysis;Berdeja;Blood,2011

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives;Critical Reviews in Oncology/Hematology;2023-07

2. How I treat relapsed multiple myeloma;Blood;2022-05-12

3. Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network;Cancer;2021-06-28

4. Current and Novel Alkylators in Multiple Myeloma;Cancers;2021-05-18

5. First‐line therapy with bendamustine/prednisone/bortezomib—A GMMG trial for non‐transplant eligible symptomatic multiple myeloma patients;European Journal of Haematology;2020-05-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3